A5005535073- Psoriasis: Treatment and Pathogenesis
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Cytokine Signaling Pathways and Interactions
- Autoimmune Bullous Skin Diseases
- Synthesis and biological activity
- Antifungal resistance and susceptibility
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Asthma and respiratory diseases
- Urological Disorders and Treatments
- Neuroendocrine Tumor Research Advances
- Cutaneous lymphoproliferative disorders research
- Monoclonal and Polyclonal Antibodies Research
- Inflammatory mediators and NSAID effects
- Cancer and Skin Lesions
- Systemic Lupus Erythematosus Research
- Biomedical Ethics and Regulation
- PI3K/AKT/mTOR signaling in cancer
- Neonatal skin health care
- Inflammatory Bowel Disease
- Retinoids in leukemia and cellular processes
- Mast cells and histamine
- Colorectal Cancer Treatments and Studies
- Chemotherapy-induced cardiotoxicity and mitigation
Bristol-Myers Squibb (United States)
2020-2025
Bristol-Myers Squibb (Germany)
2022-2023
Ospedale di Rivoli
1994
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates systemic therapy. To evaluate the safety and efficacy deucravacitinib through 4 years Phase 3 POETYK PSO-1, PSO-2 long-term extension (LTE) trials psoriasis. PSO-1 (parent trials) randomized patients 1:2:1 oral placebo, 6 mg once daily (QD) or apremilast 30 twice daily. At 52 weeks, enrolled...
Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed evaluate the effect deucravacitinib on additional and quality-of-life (QoL) outcomes assess relationship between these Post-hoc 12-week conducted for three most efficacious dosage groups (3 mg twice daily, 6 12 once daily) placebo. Investigator assessments efficacy included Psoriasis...
Safe and effective long-term treatments for moderate to severe plaque psoriasis are needed.
Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate-to-severe plaque psoriasis who are candidates systemic therapy. Deucravacitinib was superior to placebo apremilast POETYK PSO-1 (NCT03624127) PSO-2 (NCT03611751) parent trials moderate severe psoriasis. The long-term extension (LTE; NCT04036435) trial enrolled patients completing PSO-1/PSO-2. We report deucravacitinib safety...
Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates systemic therapy. Deucravacitinib was superior placebo apremilast phase 3 POETYK PSO-1 PSO-2 trials psoriasis. Upon trial completion, patients could enroll ongoing long-term extension (LTE) trial. Here, deucravacitinib safety efficacy reported through 4 years. Methods: PSO-1/PSO-2...
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor for moderate-to-severe plaque psoriasis, was superior to placebo and apremilast in two global, 52-week, phase 3 trials maintained long-term efficacy through years with no new safety signals ongoing extension (LTE) trial. We report clinical up (148 weeks) a subset of patients from these trials.
 Materials: POETYK PSO-1 PSO-2 randomized 1:2:1 oral placebo, deucravacitinib 6 mg once daily (QD), or 30...
Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate-to-severe plaque psoriasis who are candidates systemic therapy. Deucravacitinib was efficacious well-tolerated global, 52-week, phase 3 POETYK PSO-1 (NCT03624127) PSO-2 (NCT03611751) trials through 2 additional years long-term extension (LTE) (NCT04036435) trial patients treated deucravacitinib from Day 1 PSO-1/PSO-2. Here,...
Deucravacitinib demonstrated superior efficacy to apremilast in patients with moderate severe plaque psoriasis the POETYK PSO-1 and PSO-2 clinical trials. In study reported here, we aimed determine overall 52-week cumulative benefit of treatment initiated deucravacitinib versus compare initiating staying on continuing or switching at week 24 treatment. This post hoc analysis data (ClinicalTrials.gov identifier: NCT03624127) determined 6 mg once daily 30 twice adults psoriasis. Patients...
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates systemic therapy. Deucravacitinib was superior placebo apremilast two global, phase 3 trials, POETYK PSO-1 (NCT03624127) PSO-2 (NCT03611751), psoriasis. Here, we evaluate comorbidities present at baseline use prior concomitant medications pooled trial populations more...
<h3>Objective</h3> Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of moderate-to-severe plaque psoriasis. The 48-week, double-blind, phase PAISLEY trial patients with active SLE (NCT03252587) met its primary endpoint and all key secondary endpoints at deucravacitinib 3 mg twice-daily (BID) vs placebo. In this post-hoc analysis, response rates over time were evaluated ≥50% reduction Cutaneous...
Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, was superior to placebo and apremilast in two global, phase 3 trials (POETYK PSO-1 PSO-2) moderate severe plaque psoriasis. At Week 52, patients could enter the POETYK long-term extension (LTE) trial receive open-label deucravacitinib. Long-term efficacy maintained through total years of continuous treatment with no new safety signals ongoing LTE. Methods: Efficacy further evaluated 208 (4 years; data cutoff,...
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates systemic therapy. Deucravacitinib was efficacious well tolerated two global, 52-week, phase 3 POETYK PSO-1 (NCT03624127) PSO-2 (NCT03611751) parent trials, through additional years long-term extension (LTE) (NCT04036435) trial patients treated deucravacitinib from Day 1...
Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates systemic therapy. Deucravacitinib was superior placebo and apremilast the global, 52-week, phase 3 POETYK PSO-1 PSO-2 parent trials psoriasis. Upon completion, patients could enroll ongoing long-term extension (LTE) trial. Here, deucravacitinib safety/efficacy reported through 4 years. Methods:...
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates systemic therapy. Deucravacitinib was efficacious well-tolerated global, 52-week, phase 3 POETYK PSO-1 (NCT03624127) PSO-2 (NCT03611751) parent trials through additional years long-term extension (LTE) (NCT04036435) trial patients treated deucravacitinib from Day 1...
Abstract not available.
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate-to-severe plaque psoriasis who are candidates systemic therapy. Deucravacitinib was superior to placebo apremilast POETYK PSO-1 (NCT03624127) PSO-2 (NCT03611751) parent trials moderate severe psoriasis. The long-term extension (LTE; NCT04036435) trial enrolled patients completed PSO-1/PSO-2. We report safety efficacy...
Abstract not available.
Abstract not available.